Related Experiment Videos
Expression cloning of a protective Leishmania antigen
E Mougneau1, F Altare, A E Wakil
1Institut de Pharmacologie Moléculaire et Cellulaire, UPR411 CNRS, Valbonne, France.
Science (New York, N.Y.)
|April 28, 1995
Summary
Researchers identified a specific protein from the Leishmania parasite that, when used as a vaccine with interleukin-12, protected susceptible mice against infection. This finding offers a new strategy for controlling leishmaniasis.
Area of Science:
- Immunology
- Parasitology
- Molecular Biology
Background:
- CD4+ T cells mediate protection against Leishmania major infection in susceptible mouse models.
- Identifying the specific parasite antigens recognized by these T cells is crucial for vaccine development.
Purpose of the Study:
- To identify the antigen recognized by a protective CD4+ T cell clone specific to Leishmania major.
- To evaluate the vaccine potential of the identified antigen against Leishmania major infection.
Main Methods:
- Utilized an epitope-tagged expression library for antigen identification.
- Employed macrophages for antigen presentation to T cells restricted by major histocompatibility complex class II.
- Administered a vaccine composed of a portion of the identified antigen and interleukin-12 to susceptible mice before infection.
Main Results:
- Identified a conserved 36-kilodalton protein from the tryptophan-aspartic acid repeat family, expressed in both parasite life cycle stages.
- A 24-kilodalton fragment of this antigen, when used as a vaccine with interleukin-12, conferred protection in susceptible BALB/c mice against Leishmania major.
Conclusions:
- A specific Leishmania major antigen, a member of the tryptophan-aspartic acid repeat family, can induce protective immunity.
- This antigen, particularly a 24-kilodalton portion, holds promise as a component of a vaccine against leishmaniasis when combined with interleukin-12.